Concept Medical Announces Preliminary 3-Year Sirona Data at Charing Cross Symposium 2026
Preliminary 3-year data showed 88.2% freedom from repeat revascularization for MagicTouch PTA, compared with 80.2% for the paclitaxel balloon.
6 Articles
6 Articles
LONDON, April 27, 2026
Concept Medical’s MagicTouch PTA in Femoropopliteal Disease Evaluated at 3 Years in SIRONA Trial
April 29, 2026—Concept Medical Inc. announced preliminary 3-year follow-up data from the SIRONA randomized trial comparing the company’s MagicTouch PTA device, a sirolimus-coated balloon for percutaneous transluminal angioplasty (PTA), versus paclitaxel-coated balloon angioplasty in femoropopliteal artery disease. The SIRONA trial’s Principal Investigator, Professor Ulf Teichgräber, MD, presented the data at the 2026 Charing Cross Symposium. Acc…
Concept Medical Shares 3-Year SIRONA Insights at CX 2026
London [United Kingdom], April 25: At the Charing Cross Symposium 2026 this week, one theme kept resurfacing in quiet conversations between clinicians: what happens after the first year?It’s a question that doesn’t always make headlines, but it tends to shape real-world decisions. The preliminary three-year data from the SIRONA randomised trial, presented by Prof. Ulf Teichgräber, leaned directly into that gap.The study, backed by Concept Medica…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
